Avalon Investment & Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $23.8M | Buy |
584,222
+170,505
| +41% | +$7.36M | 0.65% | 47 |
|
|
2022
Q4 | $21.2M | Buy |
413,717
+113,380
| +38% | +$5.44M | 0.6% | 52 |
|
|
2022
Q3 | $13.1M | Sell |
300,337
-2,218
| -0.7% | -$108K | 0.41% | 89 |
|
|
2022
Q2 | $15.9M | Buy |
302,555
+4,680
| +2% | +$238K | 0.45% | 76 |
|
|
2022
Q1 | $15.4M | Sell |
297,875
-36,794
| -11% | -$1.91M | 0.37% | 83 |
|
|
2021
Q4 | $19.8M | Sell |
334,669
-77,220
| -19% | -$3.83M | 0.49% | 62 |
|
|
2021
Q3 | $17.7M | Sell |
411,889
-31,627
| -7% | -$1.4M | 0.41% | 74 |
|
|
2021
Q2 | $17.4M | Sell |
443,516
-69,271
| -14% | -$2.69M | 0.39% | 82 |
|
|
2021
Q1 | $18.6M | Sell |
512,787
-32,856
| -6% | -$1.17M | 0.43% | 83 |
|
|
2020
Q4 | $20.1M | Sell |
545,643
-76,245
| -12% | -$2.8M | 0.41% | 76 |
|
|
2020
Q3 | $21.7M | Sell |
621,888
-33,823
| -5% | -$1.19M | 0.48% | 63 |
|
|
2020
Q2 | $20.3M | Sell |
655,711
-150,964
| -19% | -$5.13M | 0.47% | 62 |
|
|
2020
Q1 | $25M | Sell |
806,675
-191,144
| -19% | -$6.51M | 0.64% | 46 |
|
|
2019
Q4 | $37.1M | Sell |
997,819
-69,404
| -7% | -$2.47M | 0.76% | 36 |
|
|
2019
Q3 | $36.4M | Sell |
1,067,223
-312,174
| -23% | -$11.4M | 0.8% | 33 |
|
|
2019
Q2 | $56.7M | Sell |
1,379,397
-32,052
| -2% | -$1.27M | 1.26% | 16 |
|
|
2019
Q1 | $56.9M | Sell |
1,411,449
-4,698
| -0.3% | -$188K | 1.29% | 15 |
|
|
2018
Q4 | $58.6M | Sell |
1,416,147
-20,065
| -1% | -$833K | 1.51% | 13 |
|
|
2018
Q3 | $60.1M | Sell |
1,436,212
-266,132
| -16% | -$10.2M | 1.69% | 5 |
|
|
2018
Q2 | $58.6M | Buy |
1,702,344
+7,489
| +0.4% | +$256K | 1.74% | 2 |
|
|
2018
Q1 | $57.1M | Sell |
1,694,855
-154,931
| -8% | -$5.33M | 1.76% | 4 |
|
|
2017
Q4 | $63.6M | Buy |
1,849,786
+219,862
| +13% | +$7.5M | 1.99% | 1 |
|
|
2017
Q3 | $55.2M | Buy |
1,629,924
+135,534
| +9% | +$4.36M | 1.76% | 5 |
|
|
2017
Q2 | $47.6M | Sell |
1,494,390
-13,759
| -0.9% | -$434K | 1.58% | 5 |
|
|
2017
Q1 | $49M | Buy |
1,508,149
+19,399
| +1% | +$612K | 1.68% | 6 |
|
|
2016
Q4 | $45.9M | Sell |
1,488,750
-40,762
| -3% | -$1.24M | 1.65% | 8 |
|
|
2016
Q3 | $49.1M | Sell |
1,529,512
-69,934
| -4% | -$2.34M | 1.85% | 7 |
|
|
2016
Q2 | $53.4M | Buy |
1,599,446
+657,029
| +70% | +$21M | 2.07% | 7 |
|
|
2016
Q1 | $26.5M | Sell |
942,417
-201,821
| -18% | -$5.76M | 1.15% | 29 |
|
|
2015
Q4 | $35M | Sell |
1,144,238
-36,417
| -3% | -$1.15M | 1.51% | 12 |
|
|
2015
Q3 | $35.2M | Buy |
1,180,655
+26,052
| +2% | +$835K | 1.55% | 11 |
|
|
2015
Q2 | $36.7M | Buy |
1,154,603
+5,003
| +0.4% | +$163K | 1.58% | 9 |
|
|
2015
Q1 | $37.9M | Buy |
1,149,600
+28,728
| +3% | +$913K | 1.66% | 8 |
|
|
2014
Q4 | $33.1M | Sell |
1,120,872
-141,657
| -11% | -$4.06M | 1.51% | 12 |
|
|
2014
Q3 | $35.4M | Sell |
1,262,529
-137
| -0% | -$3.85K | 1.79% | 10 |
|
|
2014
Q2 | $35.6M | Buy |
1,262,666
+11,901
| +1% | +$339K | 1.8% | 9 |
|
|
2014
Q1 | $38.1M | Buy |
1,250,765
+123,604
| +11% | +$3.69M | 2.1% | 4 |
|
|
2013
Q4 | $32.8M | Buy |
1,127,161
+9,398
| +0.8% | +$274K | 1.83% | 11 |
|
|
2013
Q3 | $30.5M | Sell |
1,117,763
-48,992
| -4% | -$1.33M | 1.97% | 8 |
|
|
2013
Q2 | $31M | Buy |
+1,166,755
| New | +$32.2M | 1.85% | 10 |
|
Other funds holding PFE
Avalon Investment & Advisory's PFE Position: Q1 2023 in Review
Avalon Investment & Advisory increased its Pfizer (PFE) stake by 41% in Q1 2023, buying an estimated $7.36M and bringing the position to 584,222 shares worth $23.8M. The position accounts for 0.65% of the portfolio, ranked #47.
Avalon Investment & Advisory first reported a position in PFE in Q2 2013 and has held it in 40 quarters since. The position peaked at $63.6M in Q4 2017. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.
- Avalon Investment & Advisory held 584,222 shares of Pfizer worth $23.8M as of Q1 2023.
- Avalon Investment & Advisory bought 170,505 Pfizer shares in Q1 2023, an estimated $7.36M.
- Pfizer made up 0.65% of Avalon Investment & Advisory's portfolio in Q1 2023, its #47 holding.
- Avalon Investment & Advisory first reported a position in Pfizer in Q2 2013 and has held it in 40 quarters since.
- Avalon Investment & Advisory's Pfizer position peaked at $63.6M in Q4 2017.
- 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.
Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.